Introduction

India's pharmaceutical sector has evolved into a global powerhouse, earning the moniker 'Pharmacy of the World' by supplying affordable medicines and vaccines to over 200 countries. Valued at $60 billion in 2026 and projected to double by 2031, the sector represents a critical pillar of India's economic growth, public health diplomacy, and self-reliance ambitions. However, structural vulnerabilities—particularly in active pharmaceutical ingredient (API) sourcing and research & development (R&D) capabilities—threaten to undermine this leadership position.

Background

India's pharmaceutical journey began post-independence with the establishment of public sector units to address medicine shortages. The Patent Act of 1970, which introduced process patents instead of product patents, catalyzed the growth of generic drug manufacturing. This policy framework enabled Indian companies to reverse-engineer patented molecules, making essential medicines affordable domestically and globally.

By the 1990s, liberalization opened the sector to private investment and foreign collaboration. India's compliance infrastructure expanded rapidly—today hosting the highest number of US FDA-approved manufacturing plants outside the United States. The sector now accounts for 10 of the world's 25 largest generic pharmaceutical firms, with pharmaceutical exports surging from $15.07 billion in 2013-14 to $27.85 billion recently.

Recent Developments

The Union Minister of Commerce & Industry's recent invitation to global pharmaceutical companies underscores India's ambition to position itself as a comprehensive healthcare hub beyond generics. Several developments mark this transition:

Manufacturing Expansion: The government's Production-Linked Incentive (PLI) scheme for pharmaceuticals, launched with an outlay of ₹15,000 crore, aims to reduce import dependency on critical bulk drugs and medical devices.

Vaccine Diplomacy: India's supply of 65-70% of WHO's global vaccine requirements was dramatically showcased during the COVID-19 pandemic through the Vaccine Maitri initiative, distributing over 250 million doses globally.

Biosimilars Growth: The biologics and biosimilars segment is expanding at 15.8% CAGR, focusing on complex therapeutics for oncology and immunology—areas with higher profit margins than traditional small-molecule drugs.

Quality Assurance: Regulatory harmonization efforts and increased inspections have strengthened India's reputation, though occasional FDA warnings highlight ongoing quality challenges.

Significance

Economic Impact: The pharmaceutical sector contributes significantly to employment, manufacturing GDP, and export earnings. The projected doubling to $120 billion by 2031 will amplify these contributions.

Public Health Security: Affordable generic medicines ensure healthcare accessibility domestically and in low- and middle-income countries, advancing Universal Health Coverage goals.

Soft Power Diplomacy: India's vaccine supply capabilities enhance its geopolitical influence, particularly in Africa, Latin America, and neighborhood countries, countering China's health diplomacy.

Innovation Ecosystem: Growth in biosimilars and specialty therapeutics positions India to move up the pharmaceutical value chain, transitioning from volume-based to value-based manufacturing.

Atmanirbhar Bharat: Strengthening domestic pharmaceutical capabilities directly supports national self-reliance objectives, especially critical in times of global supply chain disruptions.

Challenges

API Import Dependency: India's reliance on imports for approximately $4.35 billion worth of bulk drugs and intermediates annually—with 73.7% sourced from China—creates strategic vulnerability. Geopolitical tensions or supply disruptions could cripple domestic production.

R&D Investment Gap: Indian pharmaceutical companies invest only 7-8% of revenues in R&D compared to 15-25% by global innovators. This limits breakthrough drug discovery and keeps India confined to the generics space.

Quality Compliance Issues: Periodic FDA warnings regarding manufacturing violations at Indian plants damage reputation and market access. Quality consciousness must permeate the entire supply chain.

Intellectual Property Transition: As India complies with TRIPS obligations, balancing patent protection with affordable medicine access remains contentious, particularly for life-saving drugs.

Infrastructure Deficits: Despite growth, pharmaceutical parks lack world-class infrastructure, consistent power supply, and integrated logistics—increasing operational costs.

Talent Migration: Brain drain of pharmaceutical scientists to developed countries weakens India's innovation capacity.

Way Forward

API Self-Sufficiency: Accelerate implementation of the PLI scheme for bulk drugs. Establish dedicated pharmaceutical parks with integrated backward linkages for critical APIs, particularly fermentation-based products.

R&D Ecosystem Development: Create public-private partnership models for drug discovery, incentivize academia-industry collaboration, and establish Centers of Excellence for biologics, biosimilars, and novel drug delivery systems.

Quality Infrastructure: Strengthen regulatory capacity through increased inspections, mandatory good manufacturing practices (GMP) compliance, and real-time monitoring systems. Align with global pharmacopeial standards.

Innovation Incentives: Provide tax holidays and grant funding for companies investing in new chemical entities (NCEs) and orphan drug development. Establish fast-track regulatory approval pathways for innovative medicines.

Human Capital Development: Launch pharmaceutical-specific skilling programs, retain talent through competitive research opportunities, and encourage reverse brain drain through diaspora engagement.

Diversified Supply Chains: Reduce dependence on any single country for critical inputs through supplier diversification and strategic stockpiling of essential APIs.

Global Partnerships: Leverage India's manufacturing capabilities through technology transfer agreements, joint ventures with innovator companies, and participation in global health initiatives.

Conclusion

India's pharmaceutical sector stands at an inflection point—poised to transition from a volume-driven generic supplier to a comprehensive healthcare solutions provider. Addressing structural vulnerabilities in API sourcing and R&D while maintaining cost competitiveness will determine whether India sustains its 'Pharmacy of the World' status. Strategic investments, regulatory excellence, and innovation-led growth must converge to realize the sector's full potential as both an economic engine and instrument of global health equity.

Mains Practice Question

Q. While India is recognized as the 'Pharmacy of the World,' its pharmaceutical sector faces significant challenges in active pharmaceutical ingredient (API) sourcing and research & development capabilities. Critically examine these challenges and suggest a roadmap for achieving self-reliance and innovation-led growth in the pharmaceutical sector. (250 words, 15 marks)